Developing new class of bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti-tumor response.
Rondo Therapeutics
Oncology
Total Addressable Market
$10 billion+
Red Tree Board Member(s)
Red Tree Board Member
Jon Edwards, Ph.D.
Red Tree Participation
Co-led Series A
